CAR T-Cell Therapy May Serve as a Bridge to HCT in ALL – OncLive
OncLive |
CAR T-Cell Therapy May Serve as a Bridge to HCT in ALL
OncLive CAR T-cell therapy can induce next generation sequencing (NGS) negativity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL), suggesting a “synergistic” relationship with hematopoietic cell transplant (HCT) that could enhance … |
